Altimmune Reports $22.8 Million Net Loss in Q2 2026, Plans Headquarters Relocation

Altimmune, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $22.8 million, a slight increase from the $22.1 million loss recorded in the same period last year. The company did not generate any revenue during the quarter, consistent with the previous year, as it continues to focus on the development of its lead product candidate, pemvidutide, for serious liver diseases. Total operating expenses for the quarter rose to $26.2 million, up 14% from $22.9 million in the prior year, driven primarily by increased research and development costs associated with ongoing clinical trials.

For the first half of 2026, Altimmune's net loss reached $45.4 million, compared to a loss of $41.7 million in the first half of 2025. Operating expenses for this period also increased, totaling $50.5 million, a 13% rise from $44.7 million in the same timeframe last year. The increase in expenses was attributed to higher research and development costs, particularly related to the ongoing trials for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD).

In terms of financial position, Altimmune reported total assets of $527.2 million as of June 30, 2026, significantly up from $279.9 million at the end of 2025. This increase was largely due to a rise in cash and cash equivalents, which grew to $63.0 million from $43.8 million, and short-term investments, which increased to $263.3 million from $229.7 million. The company’s stockholders' equity also saw a substantial rise, reaching $474.2 million, compared to $224.9 million at the end of the previous fiscal year.

Strategically, Altimmune announced plans to relocate its corporate headquarters from Gaithersburg, Maryland, to Morristown, New Jersey, a move expected to enhance its ability to attract talent in a region with a strong biopharmaceutical presence. The company also completed a significant public offering in April 2026, raising approximately $211.1 million in net proceeds, which will support its ongoing clinical trials and operational needs. The company has begun enrolling patients in its pivotal Phase 3 trial for pemvidutide in MASH, with results anticipated in 2029.

Looking ahead, Altimmune remains focused on advancing its clinical programs and is preparing for additional trials. The company has indicated that it has sufficient capital to fund its operations for at least the next twelve months, although it may seek further financing to support its long-term growth and development objectives.